Ann: Immutep to present Phase IIb breast cancer data at ESMO 2022, page-14

Biomarker is something related to CD8+T cells "Eftilagimod also significantly increased circulating CD8-positive T cells, said Dr. Wildiers, which was significantly correlated with improved overall survival" from Eftilagimod Alpha Plus Paclitaxel May Improve Survival in HR-Positive, HER2-Negative Metastatic Breast Cancer: AIPAC Trial
Just like PD1 expression identifies responders to PD1 inhibitors measurements of Cd8+ t cells could identify a sub groups of patients with HR-Positive, HER2-Negative MBC who are going to do very well with minimal toxicity. The improvement in survival was over 18 months in some subgroups and may be a lot higher if treatment selections are made based on CD8+ T cell counts.